Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5 by van Geelen, Caroline MM et al.
RESEARCH ARTICLE Open Access
Modulation of TRAIL resistance in colon
carcinoma cells: Different contributions of
DR4 and DR5
Caroline MM van Geelen
1†, Bodvael Pennarun
1,2†, Phuong TK Le
1, Elisabeth GE de Vries
1, Steven de Jong
1*
Abstract
Background: rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer
cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor’s
contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed whether agonistic DR4 or DR5 antibodies
could be used to circumvent rhTRAIL resistance, alone or in combination with various chemotherapies.
Methods: Our study was performed in an isogenic model comprised of the SW948 human colon carcinoma cell
line and its rhTRAIL resistant sub-line SW948-TR. Effects of rhTRAIL and agonistic DR4/DR5 antibodies on cell
viability were measured using MTT assays and identification of morphological changes characteristic of apoptosis,
after acridine orange staining. Sensitivity to the different death receptor ligands was stimulated using pretreatment
with the cytokine IFN-gamma and the proteasome inhibitor MG-132. To investigate the mechanisms underlying
the changes in rhTRAIL sensitivity, alterations in expression levels of targets of interest were measured by Western
blot analysis. Co-immunoprecipitation was used to determine the composition of the death-inducing signalling
complex at the cell membrane.
Results: SW948 cells were sensitive to all three of the DR-targeting agents tested, although the agonistic DR5
antibody induced only weak caspase 8 cleavage and limited apoptosis. Surprisingly, agonistic DR4 and DR5
antibodies induced equivalent DISC formation and caspase 8 cleavage at the level of their individual receptors,
suggesting impairment of further caspase 8 processing upon DR5 stimulation. SW948-TR cells were cross-resistant
to all DR-targeting agents as a result of decreased caspase 8 expression levels. Caspase 8 protein expression was
restored by MG-132 and IFN-gamma pretreatment, which also re-established sensitivity to rhTRAIL and agonistic
DR4 antibody in SW948-TR. Surprisingly, MG-132 but not IFN-gamma could also increase DR5-mediated apoptosis
in SW948-TR.
Conclusions: These results highlight a critical difference between DR4- and DR5-mediated apoptotic signaling
modulation, with possible implications for future combinatorial regimens.
Background
Tumor necrosis factor related apoptosis inducing ligand
is a member of the tumor necrosis factor (TNF) super-
family. Recombinant human TRAIL (rhTRAIL) is cur-
rently drawing attention in the field of cancer therapy
because of its specific action in inducing apoptosis in
tumor cells. Five TRAIL-receptors have been identified
to date. The death receptors DR4 and DR5 transduce
the apoptotic signal, while three decoy receptors - decoy
receptor (DcR1), decoy receptor 2 (DcR2) and osteopro-
tegerin (OPG) - block the signal and thereby inhibit
TRAIL-mediated apoptosis [1,2]. Administration of
rhTRAIL in tumor-bearing animals has been shown to
induce significant tumor regression without systemic
toxicity [3,4]. Furthermore, rhTRAIL in combination
with chemotherapy or radiotherapy greatly enhances
anti-tumor efficacy, both in vitro and in vivo [5-8].
The TRAIL apoptotic pathway can also be stimulated
by death receptor (DR)-specific agonistic antibodies.
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either used alone or in combination with chemotherapy
(or irradiation), induce apoptosis in tumor cells in vitro
and in vivo [9-12]. Thus, both rhTRAIL and agonistic
antibodies exhibit interesting preclinical anti-tumor
properties. A phase I clinical study on rhTRAIL has
been initiated [13]. Several phase I-II clinical studies on
agonistic DR4 antibodies, as well as a phase I study on
agonistic DR5 antibodies, have also been performed
[2,14,15]. However, because rhTRAIL and DR-agonistic
antibodies differently stimulate the apoptotic signaling
cascade, drug-specific effects in the treatment of cancer
patients are expected [16-18]. rhTRAIL, which can bind
to DR4 and DR5 but also to the decoy receptors, trig-
gers cross-linking of these receptors into homo- and/or
heterotrimers [19,20]. In contrast, agonistic DR4 or DR5
antibodies have been suggested to trigger the formation
of multimeric complexes consisting of only one specific
receptor, which consequently enables them to bypass
the decoy receptors [21,22].
Not all tumor cells are sensitive to rhTRAIL, since
intrinsic or acquired resistance to this ligand can occur.
Very little is known about the specific properties of dif-
ferent DR agonists when it comes to the downstream
activation signaling pathways (e.g. NFB) and resistance
to rhTRAIL. However, rhTRAIL and agonistic anti-DR5
antibodies are known to exhibit different abilities to
induce the conformational changes in DR5 which are
required to facilitate FADD recruitment [23].
The cytokine IFN-g, and also proteasome inhibitors,
are both known to modulate components of the apopto-
tic signaling pathway involved in TRAIL resistance
[24-26]. Combinations of these drugs with TRAIL and/
or agonistic death receptor antibodies can enhance
TRAIL-induced apoptosis and overcome TRAIL resis-
tance in tumor cells [27-32]. However, potential recep-
tor specific effects on the development of resistance to
rhTRAIL have not been investigated. This is of interest,
as it has not yet been established which of the agents of
interest - DR4 antibodies, DR5 antibodies or rhTRAIL -
exhibit superior anti-tumor activity in the clinic. More-
over, it is still unknown which biomarkers should be
used to select patients for therapies specifically targeting
DR4 and DR5.
In the present study we used agonistic monoclonal
antibodies to individually evaluate the roles of DR4 and
DR5 in rhTRAIL sensitivity and TRAIL resistance. We
compared apoptosis induced by rhTRAIL with apoptosis
induced by agonistic DR4- and DR5- antibodies, taking
as our model an rhTRAIL-sensitive human colon cancer
cell line and its rhTRAIL-resistant sub-line [33].
Furthermore, we analyzed whether the effects of IFN-g
and a proteasome inhibitor in modulating apoptosis dif-
fered depending on how apoptosis was induced; that is,
we compared the modulatory effects of these com-
pounds after using agonistic DR4 and DR5 antibodies,
or rhTRAIL, to initiate apoptosis.
Methods
Reagents
We used RPMI 1640 medium obtained from Life Tech-
nologies (Breda, the Netherlands) and fetal calf serum
(FCS) from Bodinco BV (Alkmaar, the Netherlands). 3-
(4,5-dimethyl-thiazol-2-yl) 2,5-diphenyltetrazolium
bromide (MTT)-solution and CHX were purchased
from Sigma-Aldrich Chemie BV (Zwijndrecht, the
Netherlands). rhTRAIL was produced non-commercially
in cooperation with IQ-Corporation (Groningen, the
Netherlands) following a protocol described earlier [34].
To stimulate DR4, an agonistic anti-DR4 antibody
(HGS-ETR1) was used. The agonistic anti-DR5 antibo-
dies HGS-ETR2 or TR2J were used to stimulate DR5
with similar results. HGS-ETR1, HGS-ETR2 and TR2J
w e r eak i n dg i f tf r o mH u m a nG e n o m eS c i e n c e s( H G S ,
Rockville, MD, USA). The inhibiting anti-DR4 (HS 101)
and anti-DR5 (HS 201) antibodies were purchased from
Alexis (10 P’s BVBA, Breda, the Netherlands). The pro-
teasome inhibitor MG-132 was obtained from Calbio-
chem (Breda, the Netherlands), and IFN-g was
purchased from Roche Diagnostics (Mannheim, Ger-
many). The TRAIL receptor agonistic antibodies used
for flow cytometry were obtained from Immunex Cor-
poration (Seattle, WA, USA).
Cell lines
The rhTRAIL-sensitive colon carcinoma SW948 cell line
[35] was cultured as described previously [36]. The
rhTRAIL-resistant SW948-TR cell lines was generated
and cultured as described recently [33].
SDS-polyacrylamide gel electrophoresis and Western
blotting
Protein lysate preparation and Western blot analysis
were performed as described previously [36].
Co-Immunoprecipitation of TRAIL-, DR4- or DR5-DISC
DISC immunoprecipitation after TRAIL-receptor liga-
tion was performed according to Bodmer et al.[ 3 7 ]
with some modifications. Briefly, 50.10
6 cells per condi-
tion were grown, harvested and collected by centrifuga-
tion. The cell pellet was resuspended in 1 ml pre-
warmed medium, and the tube was placed in a 37°C
incubator. Recombinant human soluble flag-tagged
TRAIL and the anti-Flag monoclonal antibody M2 were
premixed for 15-30 min on ice. Cells were stimulated in
a final volume of 1 ml with 500 ng/ml Flag-tagged
TRAIL and 1.5 μg/ml M2. In unstimulated cells, the
Flag-tagged TRAIL and M2 premix were added after
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receptors. Cell suspensions were incubated for 30 min
at 37°C, and the reaction was stopped by the addition of
10 ml ice-cold phosphate buffered saline (6.4 mM
Na2HPO4;1 . 5m MK H 2PO4;0 . 1 4m MN a C l ;2 . 7m M
KCl; pH = 7.2). The cells were immediately washed with
ice-cold PBS and lysed in 1 ml lysis buffer (30 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride) with
complete protease inhibitors (Roche Diagnostics,
Almere, the Netherlands) for 15 min on ice. After cen-
trifugation (2,500 × g)a t4 ° Cf o r1 0m i n ,t h el y s a t e s
were pre-cleared with 20 μl Sepharose-6B (Pharmacia,
Uppsala, Sweden) for 2 h at 4°C and immunoprecipi-
tated with 30 μl protein-A sepharose beads for 4 h-over-
night at 4°C. Beads were washed three times with 1.5 ml
lysis buffer, resuspended in standard Western blot sam-
ple buffer, and boiled for 5 min. Immunoprecipitated
proteins were separated with SDS-PAGE. Western blot
analysis for FADD, caspase 8, c-FLIP, DR4, DR5 and
TRAIL was performed as described in the SDS-polyacry-
lamide gel electrophoresis and Western blotting section.
Goat HRP-conjugated secondary antibody specific for
mouse IgG1 and donkey-anti-goat-HRP were used for
the detection of caspase 8, FADD, c-FLIP or DR4.
DR4 and DR5-DISC co-immunoprecipitation was per-
formed as described above using the respective Human
Genome Sciences antibodies (HGS-ETR1 and TR2J),
with some modifications. Briefly, 50.10
6 cells per condi-
tion were grown in medium harvested and re-suspended
in fresh medium. Cells were stimulated with 5 μg/ml
antibody in a final volume of 2 ml. The antibodies were
added after cell lysis for the control treatment. Cell sus-
pensions were incubated for 15 min at 37°C, and the
reaction was stopped by the addition of 10 ml ice-cold
phosphate buffered saline (PBS). The cells were immedi-
ately washed with ice-cold PBS and lysed in 1 ml lysis
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.2%
Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl
fluoride) with complete protease inhibitors (Roche Diag-
nostics, Almere, the Netherlands) for 30 min on ice.
After centrifugation (12,000 × g)a t4 ° Cf o r1 0m i n ,t h e
lysates were pre-cleared with 20 μl Sepharose-6B (Phar-
macia, Uppsala, Sweden) for 2 h at 4°C and immunopre-
cipitated with 50 μl protein-G agarose beads (Roche
Diagnostics, Mannheim, Germany) for 3 at 4°C. Beads
were washed two times with 1 ml lysis buffer and one
time with PBS before resuspension in standard Western
blot sample buffer and boiling for 5 min. Immunopreci-
pitated proteins were separated with SDS-PAGE. Wes-
tern blot analysis for FADD and c-FLIP was performed
as described below. DR4 and DR5 were detected using
rabbit anti-DR4 and rabbit anti-DR5 from ProSci Inc.
(Poway, CA, USA). Caspase 8 was detected with rabbit
anti-caspase 8 (Abcam plc, Cambridge, UK). Goat anti-
rabbit HRP-conjugated secondary antibody and rabbit-
anti-mouse-HRP were used for the detection of DR4,
DR5, FADD, caspase 8 or c-FLIP.
Apoptosis assay
Apoptosis was assessed using acridine orange (AO)
staining, using a method described earlier [36].
Cytotoxicity assay
The microculture tetrazolium (MTT) assay was used to
determine cytotoxicity. SW948 and SW948-TR cells
were incubated in a total volume of 200 μl. After an
incubation period of 96 h, 20 μl of 5 mg/ml MTT solu-
tion diluted in PBS was added for 3.75 h. Subsequently,
plates were centrifuged and the supernatant aspirated.
After dissolving the formazan crystals by adding
dimethyl sulfoxide (Merck, Amsterdam, the Nether-
lands), plates were read immediately at 520 nm using a
microtiter well spectrometer (Bio-Rad microplate reader,
Bio-Rad laboratories BV, Veenendaal, the Netherlands).
Controls consisted of media without cells. Cell survival
was defined as the growth of treated cells compared
with untreated cells. IC50 was the concentration of drug
inhibiting survival by 50%. Mean cytotoxicity was deter-
mined in three independent experiments where each
condition was performed in quadruplicate.
Flow cytometry
Analysis of DR4 and DR5 membrane expression was
performed as described earlier [36]. For competition
experiments with rhTRAIL, SW948 cells (2.10
6/condi-
tion) were harvested, resuspended in 2.5 ml ice cold
PBS and incubated on ice with various amounts of
rhTRAIL for 1 h. Cells were then washed twice with
PBS before fluorescent staining for DR4 and DR5 as
described above.
Results
rhTRAIL resistance in SW948-TR can be partially explained
by its inefficient rhTRAIL-DISC formation
We developed a model for acquired rhTRAIL-resistance
consisting of the rhTRAIL-sensitive human colon carci-
noma cell line SW948 and its rhTRAIL-resistant sub-
line SW948-TR. In these two cell lines, both DR4 and
D R 5w e r ee x p r e s s e da tt h ec e l ls u r f a c e ;e x p r e s s i o no f
DR4 appeared to be higher (see Figure 1A).
We investigated whether differences in DR functional-
ity could be involved in the SW948-TR cell line’sc h a r -
acteristic resistance to rhTRAIL. TRAIL-induced DISC
formation was studied. Figure 1B shows that SW948-TR
exhibited weaker DISC recruitment of caspase 8 com-
pared with the SW948 cell line. In particular, lower
amounts of the cleaved p43/41 form of caspase 8 were
van Geelen et al. BMC Cancer 2011, 11:39
http://www.biomedcentral.com/1471-2407/11/39
Page 3 of 13measured. Other DISC proteins such as DR4 and DR5,
together with FADD and c-FLIP, were equally present
in both cell lines. In consistence with our previous find-
ings [33], the SW948-TR cell line was also characterized
by lower procaspase 8 expression level (Figure 1C).
Specific blocking of the individual death receptors
indicates that DR4 is more important than DR5 for
rhTRAIL-induced apoptosis
To evaluate the specific contributions to apoptosis of
DR4 or DR5, in the sensitive and resistant cell lines, we
used antagonistic TRAIL receptor antibodies to block
signaling at the cell surface. In SW948, rhTRAIL-induced
apoptosis was reduced by 60% using a DR4 blocking anti-
body, while blocking DR5 only had a slight effect on
rhTRAIL-induced apoptosis (Figure 2A). A competition
experiment was performed with SW948 to determine
whether rhTRAIL binding to DR4 or DR5 was affected.
SW948 cells were pretreated with rhTRAIL and kept on
ice to prevent receptor internalization, before detection
of DR4 and DR5 using flow cytometry (Figure 2B). A
similar decrease in detectable amounts of both death
receptors was observed, for a series of increasing concen-
trations of rhTRAIL. Thus, the binding of rhTRAIL was
comparable for each DR in SW948 cells.
Following initial sensitization with the protein synthesis
inhibitor CHX, SW948-TR cells were also exposed to
rhTRAIL (Figure 2C). Apoptosis was decreased by 60%
upon inhibition of rhTRAIL binding to DR4, achieved
using a DR4 blocking antibody. Inhibition with a DR5
blocking antibody had almost no effect on rhTRAIL-
induced apoptosis. Thus, blocking of DR4 and DR5 with
antagonistic antibodies revealed that DR4 was more impor-
tant than DR5 for rhTRAIL-induced apoptosis; this was
true in both SW948 and SW948-TR. In both cell lines, the
combination of both antagonistic DR- antibodies inhibited
rhTRAIL-induced apoptosis even further than the inhibi-
tion achieved using a DR4 blocking antibody alone (15.7%
additional reduction for SW948 and 31.9% reduction for
SW948-TR, compared with blocking by DR4 antibody).
This suggests that although rhTRAIL mostly signals via
DR4, both DR4 and DR5 might be important for maxi-
mum induction of the apoptotic signal using rhTRAIL.
rhTRAIL sensitivity of each DR corresponds to sensitivity
to agonistic DR4 and DR5 monoclonal antibodies
To gain more insight into the functionality of DR4 and
DR5 in apoptotic signaling, the effects of agonistic mono-
clonal DR4 and DR5 antibodies on DR-mediated apopto-
sis were determined by survival assay. As shown in
Figure 3A (left), the rhTRAIL-sensitive cell line SW948
was sensitive to both DR4 and DR5 antibodies. The ago-
nistic DR4 antibody was more effective than the agonistic
DR5 antibody, in particular at higher concentrations.
SW948-TR cells were resistant to both anti-DR4 and
anti-DR5 antibody (Figure 3A, right). These findings
were confirmed by apoptosis measured using AO stain-
ing (Figure 3B). Thus, the sensitivity of both cell lines to
agonistic DR4 or DR5 antibodies seems to partially
reflect the individual sensitivity to rhTRAIL of each
Figure 1 Inefficient DISC formation in SW948-TR cells. A:
Membrane expression of the TRAIL receptors DR4 and DR5 in
SW948 and SW948-TR cells as determined by flow cytometry. Values
are expressed as the mean fluorescence intensity (MFI) and are
mean ± SE of at least three independent experiments. B: Analysis of
the TRAIL-DISC in SW948 and SW948-TR. Cells were incubated for 30
min with Flag-tagged TRAIL and the assembled DISCs were
immunoprecipitated and analyzed by Western blotting using
antibodies to DR4, DR5, FADD, caspase 8 and c-FLIP. T = total cell
lysates; C = control of immunoprecipitation, IP =
immunoprecipitation (After a longer exposure DR5 bands were also
detectable in the total cell lysates (T)). C: Western blot analysis
comparing caspase 8 levels in SW948 and SW948-TR cells. One of at
least three independent experiments is shown.
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tic DR5 antibody, in comparison with the agonistic DR4
antibody, could be enhanced by CHX in SW948 (Figure
3B, left). CHX could also strongly sensitize SW948-TR
cells to agonistic DR4 antibody, and to a lesser extent to
agonistic DR5 antibody (Figure 3B, right).
Upon stimulation with agonistic antibodies, comparable
DISC formation occurs at the level of DR4 and DR5 in
SW948
We showed DR4 to be more competent at initiating
apoptosis than DR5 when testing SW948 cells. This was
demonstrated by stimulating each receptor with rhTRAIL
Figure 2 Important contributions of DR4 to rhTRAIL-induced apoptosis. A: Apoptosis assay in SW948. Cells were pre-incubated with 10 μg/
ml antagonistic anti-DR4 (aDR4), anti-DR5 (aDR5) antibodies or IgG1 control for 1 h before 4-5 h rhTRAIL treatment (0.1 μg/ml). Values are mean
± SD of at least three independent experiments. B: rhTRAIL binding to DR4 and DR5 in SW948 cells. Cells were incubated with increasing
concentrations of rhTRAIL before detection of accessible cell surface DR4 and DR5. Values are expressed as the mean fluorescence intensity (MFI)
and are mean ± SE of at least three independent experiments. C: Apoptosis assay in SW948-TR. CHX (5 μg/ml) was combined or not with the
blocking antibodies 1 h before TRAIL treatment as described in (A).
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mulating each receptor with agonistic antibodies only. To
investigate possible differences in DR4-DISC versus DR5-
DISC formation, we stimulated SW948 cells with either
agonistic DR4 or DR5 antibody, and individually co-
immunoprecipitated DR4- and DR5-DISC (Figure 4A).
Surprisingly, DISC formation was comparable for both
stimuli. Agonistic DR4 antibody was capable of recruiting
DR4, FADD, caspase 8 and c-FLIP. Using an antibody
directed against the N-terminal fragment of caspase 8,
three forms of this protein were detected in the DR4-
DISC: the full form, the intermediate p43/41 cleaved
form and the p26/24 cleavage product. That the latter
form was detectable indicates full cleavage of caspase 8,
and thereby release of active caspase 8 from the complex
(for comprehensive review see [38]). c-FLIP was mostly
present in its intermediate form. The agonistic DR5 anti-
body recruited DR5 and similar amounts of FADD, c-
FLIP and caspase 8 as compared with the agonistic DR4
antibody. Caspase 8 cleavage was also investigated in
whole cell lysates of SW948 cells treated with either one
of the agonistic DR antibodies (Figure 4B). Within
3 hours, the agonistic DR4 antibody induced full cleavage
of the available procaspase 8 into its intermediate and
active form. Caspase 8 cleavage in cells stimulated with
agonistic DR5 antibody was only partial, as active caspase
8 could not be detected, while unprocessed procaspase
8 molecules were still present after 3 hours.
Figure 3 Sensitivity of SW948 and SW948-TR cells to agonistic DR4 and DR5 antibodies. A: Survival (%) of SW948 and SW948-TR after
continuous incubation with agonistic DR4 antibody and agonistic DR5 antibody as measured by cytotoxicity assays. B: Apoptosis assay in SW948
and SW948-TR. Cells were pre-incubated with 5 μg/ml CHX for 1 h before incubation with various concentrations of agonistic DR4 antibody
(DR4 Ab) and agonistic DR5 antibody (DR5 Ab) for 24 h.
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antibody can be overcome by the proteasome inhibitor
MG-132
Several studies have demonstrated that proteasome inhi-
bition can overcome rhTRAIL-resistance [24,39,40]. Pre-
viously, we have observed that SW948-TR could be
sensitized to rhTRAIL using the proteasome inhibitor
MG-132 [33]. To investigate whether MG-132 sensitized
cells in receptor-specific manner, we pre-incubated
SW948-TR cells with this compound before treating
them with rhTRAIL or agonistic anti-DR4 and -DR5
antibodies. Following MG-132 treatment, we observed
that apoptosis induced by either agonistic DR4 or DR5
antibody was enhanced by approximately 50-60%. This
effect was similar to the observed enhancement of
rhTRAIL-induced apoptosis (Figure 5A). As seen in
figure 5B, these effects were not the result of cell mem-
brane DR4 (left figure) or DR5 (right figure) up-regula-
tion by MG-132. Western blot analysis demonstrated
that MG-132 increased the intermediate p43/41 cleavage
product of caspase 8 (Figure 5C). The combination of
MG-132 with rhTRAIL, agonistic DR4 or DR5 antibody
led to an almost identical processing of caspase 8 into
its active caspase 8 subunit (p18).
IFN-g sensitizes SW948-TR to rhTRAIL and agonistic DR4
antibody but not to agonistic DR5 antibody
Upregulation of caspase 8 by IFN-g has been described
as a mechanism of sensitization to rhTRAIL [41].
Reduced caspase 8 expression levels were detected in
SW948-TR as compared with SW948 (figure 1C), which
is causative for the observed rhTRAIL resistance in
these cells [33]. We therefore hypothesized that IFN-g
might overcome rhTRAIL resistance in SW948-TR.
Upon treatment with IFN-g, caspase 8 protein expres-
sion was enhanced in a concentration-dependent man-
ner, in both cell lines (figure 6A). IFN-g treatment
slightly downregulated DR5 but not DR4 surface levels
(Figure 6B left and right, respectively). In a previous
study we did not observe any additional effect of IFN-g
on rhTRAIL sensitivity in SW948, a cell line that is
already extremely sensitive to rhTRAIL [36]. In the cur-
rent study, survival assays showed that IFN-g could sen-
sitize SW948-TR to both rhTRAIL and agonistic DR4
antibody but not to DR5 antibody (Figure 7A). Similar
results were also seen in an apoptosis assay using AO
staining (Figure 7B). Cell survival assays in SW948 indi-
cated that IFN-g enhanced the sensitivity to agonistic
DR4 antibody but not to DR5 antibody (results not
shown). TRAIL receptor blocking antibodies were used
to determine the relative contribution of each individual
DR to IFN-g induced sensitization to rhTRAIL in
SW948-TR. The observed sensitization to rhTRAIL was
DR4 specific. The DR4 blocking antibody reduced
rhTRAIL-induced apoptosis by 50%, whereas the DR5
blocking antibody only had a minor effect on apoptosis
in SW948-TR cells pre-sensitized with IFN-g (Figure
7C). Western blot analysis of caspase 8 cleavage was
performed to gain further insights into the possible
mechanism underlying IFN-g-induced sensitization of
DR-mediated apoptosis in SW948-TR cells (Figure 7D
and 7E). Treatment with IFN-g elevated procaspase 8
levels and induced cleavage of procaspase 8 into the
intermediate p43/41 product. The combination of IFN-g
with rhTRAIL or agonistic DR4 antibody induced clea-
vage of caspase 8 to its p18 active form. When cells
were treated with IFN-g and agonistic DR5 antibody,
only the intermediate form of caspase 8 (p43/41) could
Figure 4 Equivalent DISC protein recruitment, but not caspase
8 activation, following agonistic DR4 and DR5 antibody
treatment. A: Analysis of the DR4 and DR5-DISC in SW948. Cells
were incubated for 15 min with agonistic DR4 and DR5 antibodies
before co-immunoprecipitation of the associated DISCs using
protein G-agarose beads, and subsequent analysis by Western
blotting using antibodies directed against DR4, DR5, FADD, caspase
8 and c-FLIP. Post = antibodies added after cell lysis; Stim = cells
stimulated with the indicated antibody for 15 min. One
representative of at least two independent experiments is shown. B:
Time-dependent cleavage of pro-caspase 8 in SW948 cells treated
with 50 nM agonistic DR4 and DR5 antibodies.
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tive combination; that is, agonistic DR5 antibody with
MG-132 (see Figure 5C). This suggests that only DR4-
mediated apoptosis benefits from the increase in caspase
8l e v e l si nI F N - g pretreated cells. We also assessed
whether IFN-g modulated c-FLIP levels. Changes in c-
FLIP expression could have affected caspase 8 cleavage in
response to the various pro-apoptotic TRAIL receptor
ligands (see Additional file 1). Western-blot analysis
showed that IFN-g induced some cleavage of c-FLIP.
However, IFN-g did not change basal c-FLIP levels.
Discussion
DISC formation is the first step toward apoptosis after
engagement of DR4 and DR5 by their ligands. Not sur-
prisingly, resistance to TRAIL-mediated apoptosis is
often initiated at the level of the DISC [42]. We
observed that upon stimulation with TRAIL, all canoni-
cal DISC proteins were recruited to DR4 and DR5 in
SW948 and SW948-TR cells. In relation to the other
DISC proteins, smaller amounts of cleaved caspase 8
were found in the TRAIL-DISC of SW948-TR cells as
compared with SW948 cells. These results were in
agreement with the lower basal caspase 8 protein levels
found in SW948-TR. Altogether, these findings suggest
less active recruitment and processing of caspase 8 in
our resistant cell line. We also describe a difference in
apoptosis-inducing ability between DR4 and DR5.
Despite equivalent initial DISC formation at the level of
each receptor, DR4 stimulation achieves superior cas-
pase 8 processing than DR5.
Antagonistic DR4 or DR5 antibodies were used to spe-
cifically block the function of their respective receptors
during rhTRAIL-induced apoptotic signaling. Experi-
ments with these blocking antibodies proved that DR4
was critical to rhTRAIL-induced apoptotic signaling in
both cell lines; DR5 was not. It was previously reported
that apoptosis induction in keratinocytes with leucine
zipper TRAIL was also mainly mediated by DR4 [43]. In
contrast, Kelley et al. generated receptor-selective
mutants of TRAIL, with three to six ligand amino acid
substitutions [17], and found DR5 to be more important
for apoptotic signaling than DR4 in cancer cells expres-
sing both receptors (including colon cancer cells). Van
der Sloot et al. demonstrated that DR5-selective TRAIL
variants did not induce apoptosis in cell lines mostly
responsive to DR4 stimuli, while they greatly stimulated
apoptosis in DR5-responsive cancer cell lines [44]. Little
is known about the mechanisms underlying these differ-
ences. Blocking of both DR4 and DR5 prevented apop-
tosis more efficiently than single blocking of DR4, which
suggests that DR5 also contributes to rhTRAIL-induced
apoptosis. While DR4 was more potent in transducing
apoptosis, DR5 might, at least in our model, increase
the overall apoptotic stimulus compared with DR4 sti-
mulation alone.
We found that in SW948 and SW948-TR cells, sensi-
tivity to agonistic DR4 and DR5 antibody mostly
reflected the sensitivity of each receptor to rhTRAIL.
Although the agonistic DR4 antibody was more potent
than its anti-DR5 counterpart, agonistic DR5 antibody
could induce apoptosis to some extent in SW948 cells,
and also in SW948-TR following pre-sensitization with
CHX. This strongly suggests that DR5 is functional in
both cell lines, as also indicated by rhTRAIL binding
Figure 5 Sensitization of SW948-TR cells to rhTRAIL, agonistic
DR4 and DR5 antibodies by MG-132. A: Apoptosis assay in
SW948-TR after 17 h of incubation with MG-132 in combination
with rhTRAIL, agonistic DR4 or DR5 antibody. B: The effect of MG-
132 on DR4 (left figure) and DR5 (right figure) membrane
expression as determined by flow cytometry. Receptor expression
was detected as the average antigenic density of the whole cell
population and resulted in a peak shift to the right. (1 = control; 2
= basal DR4 or DR5 membrane expression level; 3 = DR4 or DR5
expression after exposure to 10 μM MG-132 for 17 h). C: Western
blot analysis of caspase 8 activation in SW948-TR after 17 h
incubation with 1 μM MG-132 in combination with rhTRAIL (0.1 μg/
ml), agonistic DR4 or DR5 antibody (50 nM).
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Georgakis et al. found that in primary non-Hodgkin’s
lymphoma samples, an agonistic DR4 antibody was also
more effective than an agonistic DR5 antibody [16].
We investigated the ability of each receptor to initiate
DISC formation and caspase 8 cleavage in SW948 by co-
immunoprecipitating DR4- and DR5-DISC. Similar DISC
formation and caspase 8 cleavage were triggered at the
level of both receptors, although the rate of caspase 8 pro-
cessing was much higher in whole cell lysates when cells
were stimulated with agonistic DR4 antibody instead of
agonistic DR5 antibody. This is consistent with our recent
findings that caspase 8 cleavage at the level of DR5-DISC
in SW948 is limited due to a lower turn-over of DISC
components rather than to decreased DISC formation
[45]. Data on such DISC protein turn-over following
TRAIL receptor stimulation are limited. However, studies
by McDonald et al. and Jin et al. have suggested that cas-
pase 8 ubiquitination influences processing of the available
caspase 8 cellular pool [46,47]. Brief pre-incubation with
Figure 6 Increase in caspase 8 levels following treatment of SW948-TR cells with IFN-g. A: Effects of 48 h incubation with increasing
concentrations of IFN-g on caspase 8 levels in SW948 and SW948-TR. B: Effects of IFN-g on DR4 (left figure) and DR5 (right figure) membrane
expression as determined by flow cytometry. Receptor expression was detected as the average antigenic density of the whole cell population
and resulted in a peak shift to the right. (1 = control; 2 = basal DR4 or DR5 membrane expression level; 3 = DR4 or DR5 expression after
exposure to 1000 units (U)/ml IFN-g for 48 h).
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Page 9 of 13Figure 7 Stimulation of rhTRAIL- and agonistic DR4 antibody-induced but not agonistic DR5 antibody-induced apoptosis by IFN-g. A:
Survival (%) of SW948-TR cells after continuous incubation with rhTRAIL, agonistic DR4 or DR5 antibody in combination with different
concentrations of IFN-g. B: Apoptosis assay of SW948-TR after 48 h incubation with rhTRAIL, agonistic DR4 or DR5 antibody in combination with
various concentrations of IFN-g. C: Apoptosis assay in SW948-TR after 48 h incubation with 1000 U/ml IFN-g. Cells were then incubated with 10
μg/ml antagonistic anti-DR4 (aDR4), anti-DR5 (aDR5) antibodies, both (aDR4/5) or IgG1 control for 1 h before 4-5 h rhTRAIL treatment (0.1 μg/
ml). D: Western blot analysis of caspase 8 activation in SW948-TR cells. The cells were pre-incubated for 48 hours with 1000 U/ml IFN-g, then
either left untreated or exposed for 4-5 additional hours with rhTRAIL (0.1 μg/ml) before harvest. E: Western blot analysis of caspase 8 activation
in SW948-TR cells. The cells were pre-incubated for 48 hours with 1000 U/ml IFN-g, then either left untreated or exposed for 4-5 additional hours
with agonistic DR4 antibody (50 nM) or agonistic DR5 antibody (50 nM) before harvest.
van Geelen et al. BMC Cancer 2011, 11:39
http://www.biomedcentral.com/1471-2407/11/39
Page 10 of 13CHX could also restore DR5-mediated caspase 8 cleavage
and sensitivity; a short-lived protein might, therefore, be
involved in this process.
IFN-g is known to increase caspase 8 expression and,
consequently, to sensitize cancer cells (including colon
cancer cells) to rhTRAIL [24,41,48-50]. Our results are
in slight contrast to these findings, as upregulation of
caspase 8 by IFN-g did not further enhance apoptosis
induction in the highly sensitive SW948 cells. Caspase 8
levels might not be a limiting factor in these cells, since
procaspase 8 recruitment to the DISC is first deter-
mined by the amount of FADD molecules available
there [51]. IFN-g did, however, increase apoptosis induc-
tion by rhTRAIL and agonistic DR4 antibody in SW948-
TR cells, which express lower caspase 8 levels than their
parental cells. In SW948-TR, IFN-g induced a marked
increase in both pro- and intermediate forms of caspase
8, which were cleaved to the active form upon DR4 sti-
mulation. Downregulation of caspase 8 levels in SW948
- that is, to a level comparable to that which is normally
observed in SW948-TR cells - was sufficient to induce
TRAIL resistance, indicating the importance of the cas-
pase-8/c-FLIP ratio in these cells [33]. It is noteworthy
that IFN-g, while inducing an increase in caspase 8
levels, did not change c-FLIP expression in SW948-TR.
In contrast, IFN-g failed to enhance the appearance of
active caspase 8 following DR5 stimulation. This was
shown using agonistic DR5 antibody, but also rhTRAIL
in combination with DR4 blocking antibodies. The slight
reduction in DR5 surface expression may explain the
lack of increase in DR5-mediated apoptosis.
Unlike IFN-g, MG-132 markedly increased both DR4-
and DR5-mediated sensitivity in SW948-TR cells.
Another proteasome inhibitor, bortezomib, was pre-
viously reported to enhance the effect of agonistic DR4
and agonistic DR5 antibody in Hodgkin’s disease cell
lines [18,52]. MG-132 could increase TRAIL-induced
apoptosis in both Bax-deficient and proficient colon can-
cer cells, which is suggestive of a sensitization mechanism
independent of the mitochondrial pathway of apoptosis
[24]. DR4 and DR5 upregulation by proteasome inhibitors
is thought to be a major factor contributing to TRAIL-
induced apoptosis sensitization. However, this hypothesis
has been subject to an extensive debate [53]. We found
that upon MG-132 treatment, DR4-mediated sensitivity
increased in the absence of DR4 upregulation. The inter-
mediate form of caspase 8 was upregulated by MG-132,
an event which we found was sufficient to restore sensi-
tivity to agonistic DR4 antibody or rhTRAIL following
IFN-g treatment. Importantly, MG-132 also increased
caspase 8 cleavage and enhanced DR5-mediated apopto-
sis. MG-132 has previously been shown to modulate DR5
expression [24,54]. Our flow cytometry analysis only
showed negligible DR5 upregulation by MG-132, which
again points to a mechanism of sensitization independent
of this effect. MG-132 upregulated caspase 8 in SW948-
TR, but we demonstrated using IFN-g that restoring cas-
pase 8 levels was not sufficient to increase DR5-mediated
caspase 8 cleavage and apoptosis. Taken together, these
results support the existence of additional sensitizing
mechanisms of MG-132 at the level of DR5-DISC,
beyond DR5 and caspase 8 upregulation. Many of the
proteins involved in the DR-mediated apoptotic pathways
are regulated by ubiquitination [55], and some of these
proteins could play a crucial role in specific regulation of
DR5 signaling.
In particular, understanding how MG-132 can over-
come DR5-resistance may be of crucial importance, since
Johnsen et al.p r e v i o u s l yr e p o r t e dt h a tI F N - g failed to
increase TRAIL-induced apoptosis in 3 out of 8 neuro-
blastoma cancer cell lines; this result occurred despite
caspase 8 upregulation and in the presence of all the pro-
teins known to be necessary for DISC formation [41]. It
would be interesting to verify whether DR4 signaling
remains functional in the non-responding cells. Further-
more, in view of the large number of agents in clinical
development targeting DR5, as opposed to DR4, a deeper
knowledge on DR5-mediated signaling regulation is criti-
cal for a more rational design of targeted therapies.
Conclusions
We have demonstrated that cell sensitivity to rhTRAIL
signaling via DR4 and DR5 mostly coincides with sensi-
tivity to agonistic DR4 and DR5 antibodies, respectively.
In SW948-TR cells, apoptosis induced by DR4 stimuli
seems to be limited by the lesser amounts of caspase 8
available (in comparison with the parental cell line).
Resistance to DR5-mediated apoptosis in SW948-TR
cells most likely stems from a combination of at least two
mechanisms: (1) low caspase 8 levels and (2) sub-optimal
capacity to process the existing caspase 8 at the level of
this receptor, which was also seen in the parent cell line.
Only MG-132 was able to restore generation of active
caspase 8, upon DR5-stimulation, in the SW948-TR line.
These results underscore the DR-specificity of drug com-
binations and demonstrate the presence of different resis-
tance mechanisms at the level of DR4 and DR5.
Additional material
Additional file 1: Effects of IFN-g on c-FLIP cleavage. Western blot
analysis of c-FLIP levels in SW948-TR after 48 h preincubation with 1000
U/ml IFN-g in combination with rhTRAIL (0.1 μg/ml), agonistic DR4 or
DR5 antibody (50 nM) treatment for 5 h.
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